Bain uses cookies to improve functionality and performance of this site. More information can be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

We have limited Spanish content available. View Spanish content.

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

  • enero 04, 2016
  • min read

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

BioPharma Dive tapped into the expertise of top thought leaders in the industry to get their takes on what comes next in pricing, M&As, drug development, transparency and much more. "Bain has demonstrated how biopharma leaders have created the most shareholder value by focusing on a few, sustainable leadership positions in Product Categories (distinct from Therapeutic Areas)," said Ashish Singh, the leader of Bain & Company's Global Healthcare practice. "This focused strategy of Category Leadership has been proven to provide superior returns on investment in R&D and commercial."